경카테터 심장판막 시장 : 유형, 기술, 유통, 용도별 - 세계 예측(2025-2030년)

The Transcatheter Heart Valve Market was valued at USD 3.58 billion in 2023, expected to reach USD 3.96 billion in 2024, and is projected to grow at a CAGR of 11.34%, to USD 7.59 billion by 2030.

The transcatheter heart valve market is characterized by its innovative approach to treating heart valve diseases, particularly aortic stenosis, by using minimally invasive techniques. This market spans the necessity to provide an alternative for patients who are at high risk for open-heart surgery, enabling quicker recovery times and less hospital stays. The primary application is in transcatheter aortic valve replacement (TAVR), with potential extension into mitral and pulmonary valve replacements. End-use scope primarily includes hospitals and cardiac centers. Key growth influencers in this market include an aging global population with increasing incidences of heart valve diseases, technological advancements in valve designs, and growing demand for minimally invasive procedures. Factors driving growth also encompass rising healthcare expenditure and improving reimbursement scenarios across major markets.

However, the market faces limitations such as high costs associated with transcatheter heart valve procedures, stringent regulatory approvals, and potential risks including stroke and valve complications. Additionally, market growth could be challenged by reimbursement hurdles in emerging economies and a limited number of skilled healthcare professionals who can perform these complex procedures.

Opportunities lie in exploring untapped markets in Asia-Pacific and Latin America, where growing awareness and infrastructural development can drive demand. Effective partnerships between healthcare providers and manufacturers can facilitate market penetration in these regions. Innovation can focus on enhancing biocompatibility and longevity of valve materials, and further miniaturization of devices to broaden patient eligibility. Research areas with the potential for significant impact include developing next-generation valve platforms and improving procedural techniques that enhance patient outcomes.

As the market is competitive yet has considerable room for growth, firms should invest in R&D and collaborate with clinical institutions to bring forth cutting-edge solutions. Adapting to regulatory shifts and focusing on cost-effective production can also be pivotal in maintaining a competitive edge in this rapidly evolving sector.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Transcatheter Heart Valve Market

The Transcatheter Heart Valve Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Surging aging population and increasing incidences of heart disease and disorders
  • Increasing awareness and favorable reimbursement policies for heart health
  • Government initiatives to raise access to healthcare for treating heart conditions
• Market Restraints
  • Need for skilled personnel and complexity in handling transcatheter heart valve
• Market Opportunities
  • Ongoing advances in medical technology to create accurate, safe transcatheter heart valves
  • Evolving patient preferences for personalized healthcare and treatment solutions
• Market Challenges
  • Concerns related to valve durability and safety

Porter's Five Forces: A Strategic Tool for Navigating the Transcatheter Heart Valve Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Transcatheter Heart Valve Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Transcatheter Heart Valve Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Transcatheter Heart Valve Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Transcatheter Heart Valve Market

A detailed market share analysis in the Transcatheter Heart Valve Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Transcatheter Heart Valve Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Transcatheter Heart Valve Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Transcatheter Heart Valve Market

A strategic analysis of the Transcatheter Heart Valve Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Transcatheter Heart Valve Market, highlighting leading vendors and their innovative profiles. These include 4C Medical Technologies, Inc., Abbott Laboratories, Auto Tissue Berlin GmbH, Boston Scientific Corporation, Bracco S.p.A., Colibri Heart Valve, LLC, CoreMedic, Cryolife Inc., Edwards Lifesciences Corporation, Foldax, Inc., Hansen Medical Inc. by Auris Surgical Robotics Inc., JC Medical, Inc. by Genesis Group, JenaValve, Lepu Medical Technology Co., Ltd, LivaNova PLC, Mardil Medical, Medtronic PLC, Meril Life Sciences, NVT AG, SentreHEART by AtriCure, Stryker Corp., and XELTIS.

Market Segmentation & Coverage

This research report categorizes the Transcatheter Heart Valve Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Type, market is studied across Transcatheter Aortic Valve, Transcatheter Mitral Valve, and Transcatheter Pulmonary Valve.
• Based on Technology, market is studied across Balloon Expanded Transcatheter Valve and Self-Expanded Transcatheter Valve.
• Based on Distribution, market is studied across Cardiology Clinics, Hospitals, and Research & Academic Institutions.
• Based on Application, market is studied across Aortic Stenosis and Mitral Regurgitation.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Surging aging population and increasing incidences of heart disease and disorders
    • 5.1.1.2. Increasing awareness and favorable reimbursement policies for heart health
    • 5.1.1.3. Government initiatives to raise access to healthcare for treating heart conditions
  • 5.1.2. Restraints
    • 5.1.2.1. Need for skilled personnel and complexity in handling transcatheter heart valve
  • 5.1.3. Opportunities
    • 5.1.3.1. Ongoing advances in medical technology to create accurate, safe transcatheter heart valves
    • 5.1.3.2. Evolving patient preferences for personalized healthcare and treatment solutions
  • 5.1.4. Challenges
    • 5.1.4.1. Concerns related to valve durability and safety
• 5.2. Market Segmentation Analysis
  • 5.2.1. Type: Usage of the transcatheter aortic valve (TAV) in treating aortic stenosis among the aging population
  • 5.2.2. Distribution: Expansion of hospital infrastructure and provision of comprehensive medical care
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Transcatheter Heart Valve Market, by Type

• 6.1. Introduction
• 6.2. Transcatheter Aortic Valve
• 6.3. Transcatheter Mitral Valve
• 6.4. Transcatheter Pulmonary Valve

7. Transcatheter Heart Valve Market, by Technology

• 7.1. Introduction
• 7.2. Balloon Expanded Transcatheter Valve
• 7.3. Self-Expanded Transcatheter Valve

8. Transcatheter Heart Valve Market, by Distribution

• 8.1. Introduction
• 8.2. Cardiology Clinics
• 8.3. Hospitals
• 8.4. Research & Academic Institutions

9. Transcatheter Heart Valve Market, by Application

• 9.1. Introduction
• 9.2. Aortic Stenosis
• 9.3. Mitral Regurgitation

10. Americas Transcatheter Heart Valve Market

• 10.1. Introduction
• 10.2. Argentina
• 10.3. Brazil
• 10.4. Canada
• 10.5. Mexico
• 10.6. United States

11. Asia-Pacific Transcatheter Heart Valve Market

• 11.1. Introduction
• 11.2. Australia
• 11.3. China
• 11.4. India
• 11.5. Indonesia
• 11.6. Japan
• 11.7. Malaysia
• 11.8. Philippines
• 11.9. Singapore
• 11.10. South Korea
• 11.11. Taiwan
• 11.12. Thailand
• 11.13. Vietnam

12. Europe, Middle East & Africa Transcatheter Heart Valve Market

• 12.1. Introduction
• 12.2. Denmark
• 12.3. Egypt
• 12.4. Finland
• 12.5. France
• 12.6. Germany
• 12.7. Israel
• 12.8. Italy
• 12.9. Netherlands
• 12.10. Nigeria
• 12.11. Norway
• 12.12. Poland
• 12.13. Qatar
• 12.14. Russia
• 12.15. Saudi Arabia
• 12.16. South Africa
• 12.17. Spain
• 12.18. Sweden
• 12.19. Switzerland
• 12.20. Turkey
• 12.21. United Arab Emirates
• 12.22. United Kingdom

13. Competitive Landscape

• 13.1. Market Share Analysis, 2023
• 13.2. FPNV Positioning Matrix, 2023
• 13.3. Competitive Scenario Analysis
  • 13.3.1. Edwards Lifesciences Introduces SAPIEN 3 Ultra RESILIA Heart Valve in Europe, Offering Advanced Solution for Aortic Valve Disease
  • 13.3.2. FDA Approves Medtronic's Advanced Evolut FX+ TAVR System for Severe Aortic Stenosis
  • 13.3.3. Abbott Unveils Navitor Vision, Advanced Transcatheter Heart Valve Technology Aims to Improve Patient Outcomes
• 13.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. 4C Medical Technologies, Inc.
• 2. Abbott Laboratories
• 3. Auto Tissue Berlin GmbH
• 4. Boston Scientific Corporation
• 5. Bracco S.p.A.
• 6. Colibri Heart Valve, LLC
• 7. CoreMedic
• 8. Cryolife Inc.
• 9. Edwards Lifesciences Corporation
• 10. Foldax, Inc.
• 11. Hansen Medical Inc. by Auris Surgical Robotics Inc.
• 12. JC Medical, Inc. by Genesis Group
• 13. JenaValve
• 14. Lepu Medical Technology Co., Ltd
• 15. LivaNova PLC
• 16. Mardil Medical
• 17. Medtronic PLC
• 18. Meril Life Sciences
• 19. NVT AG
• 20. SentreHEART by AtriCure
• 21. Stryker Corp.
• 22. XELTIS